Coral García

发表

Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

P. Soler-Palacín, Á. Holguín, J. Losa, 2020, Scientific Reports.

No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients

P. Viciana, L. López-Cortés, J. Pasquau, 2018, PloS one.

Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant

J. Losa, J. Bisbe, S. Reus, 2018, Open forum infectious diseases.

Weight changes after first-line antiretroviral initiation in a cohort of HIV-positive patients in Southern Spain (CAPOTA study)

A. Rivero, C. Hidalgo-Tenorio, Jesús Santos, 2022, International journal of STD & AIDS.

HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018

S. Reus, L. Force, C. Rodríguez, 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

DOLAMA study

C. Hidalgo-Tenorio, Jesús Santos, J. Pasquau, 2019, Medicine.

Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network

D. Konopnicki, L. T. Te Brake, A. Colbers, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study.

J. Lambert, J. Rockstroh, D. Konopnicki, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients

C. Hidalgo-Tenorio, Jesús Santos, J. Pasquau, 2019 .

Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

J. Losa, J. Navarro, L. Force, 2022, HIV medicine.

Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network

J. Lambert, J. Rockstroh, D. Konopnicki, 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure

P. Soler-Palacín, Á. Holguín, J. Losa, 2021, The Journal of antimicrobial chemotherapy.

First pharmacokinetic data of bictegravir in pregnant women living with HIV.

C. Hidalgo-Tenorio, A. Colbers, Coral García, 2021, AIDS.